Long-term Safety of Ozanimod in Patients with Moderately to Severely Active Ulcerative Colitis (UC) and Relapsing Multiple Sclerosis (RMS) Studies

被引：0
|
作者：
Rubin, David T. [1 ]
Wolf, Douglas C. [2 ]
Alekseeva, Olga [3 ]
Charles, Lorna [4 ]
Afsari, Sonia [4 ]
Petersen, Ann Katrin [5 ]
Sheffield, James [4 ]
Li, Hongjuan [4 ]
Silva, Diego [4 ]
Lublin, Fred D. [6 ]
Cree, Bruce [7 ]
Cohen, Jeffrey [8 ]
Danese, Silvio [9 ]
机构：
[1] Univ Chicago Med, Ctr Inflammatory Bowel Dis, Chicago, IL USA
[2] Atlanta Gastroenterol Associates, Ctr Crohns Dis & Ulcerat Colitis, Atlanta, GA USA
[3] Nizhni Novgorod Reg Clin Hosp, Nizhnii Novgorod, Nizhegorod, Russia
[4] Bristol Myers Squibb, Princeton, NJ USA
[5] Bristol Myers Squibb, Princeton, CA USA
[6] Icahn Sch Med Mt Sinai, New York, NY 10029 USA
[7] Univ Calif San Francisco, UCSF Weill Inst Neurosci, San Francisco, CA 94143 USA
[8] Mellen Ctr Multiple Sclerosis Treatment & Res, Cleveland, OH USA
[9] Humanitas Clin & Res Ctr IRCCS & Hunimed, Ctr Inflammatory Bowel Dis, Milan, Lombardia, Italy
来源：
AMERICAN JOURNAL OF GASTROENTEROLOGY | 2021年 / 116卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
S853
引用
收藏
页码：S396 / S396
页数：1
相关论文
共 50 条
  • [21] Predictors of time to relapse upon ozanimod withdrawal in patients with moderately to severely active ulcerative colitis
    Vermeire, S.
    Abraham, B.
    Bressler, B.
    Reinisch, W.
    Axelrad, J. E.
    Jain, A.
    Memaj, A.
    Akukwe, L.
    Liu, W. J.
    Osterman, M. T.
    Canavan, J. B.
    Sands, B. E.
    JOURNAL OF CROHNS & COLITIS, 2023, 17 : 882 - 884
  • [22] Concomitant Administration of Ozanimod and Serotonergic Antidepressants in Patients With Ulcerative Colitis or Relapsing Multiple Sclerosis
    Regueiro, Miguel
    Siegmund, Britta
    Horst, Sara
    Moslin, Ryan
    Charles, Lorna
    Petersen, AnnKatrin
    Tatosian, Daniel
    Wu, Hsiuanlin
    Lawlor, Garrett
    Fischer, Monika
    D'Haens, Geert
    Colombel, Jean-Frederic
    INFLAMMATORY BOWEL DISEASES, 2024,
  • [23] Long-Term Efficacy and Safety of Ozanimod in Moderately to Severely Active Ulcerative Colitis: Results From the Open-Label Extension of the Randomized, Phase 2TOUCHSTONE Study
    Sandborn, William J.
    Feagan, Brian G.
    Hanauer, Stephen
    Vermeire, Severine
    Ghosh, Subrata
    Liu, Wenzhong J.
    Petersen, AnnKatrin
    Charles, Lorna
    Huang, Vivian
    Usiskin, Keith
    Wolf, Douglas C.
    D'Haens, Geert
    JOURNAL OF CROHNS & COLITIS, 2021, 15 (07): : 1120 - 1129
  • [24] Efficacy and safety of adalimumab in Japanese patients with moderately to severely active ulcerative colitis
    Yasuo Suzuki
    Satoshi Motoya
    Hiroyuki Hanai
    Takayuki Matsumoto
    Toshifumi Hibi
    Anne M. Robinson
    Nael M. Mostafa
    Jingdong Chao
    Vipin Arora
    Anne Camez
    Roopal B. Thakkar
    Mamoru Watanabe
    Journal of Gastroenterology, 2014, 49 : 283 - 294
  • [25] Integrated summary of safety of obefazimod for patients with moderately to severely active ulcerative colitis
    Vermeire, S.
    Peyrin-Biroulet, L.
    Danese, S.
    Dubinsky, M.
    Dulai, P. S.
    Tilg, H.
    Siegmund, B.
    Hisamatsu, T.
    Shan, K.
    Jacobstein, D.
    Cataldi, F.
    Rabbat, C.
    Sands, B. E.
    JOURNAL OF CROHNS & COLITIS, 2025, 19 : i1554 - i1555
  • [26] Efficacy and safety of adalimumab in Japanese patients with moderately to severely active ulcerative colitis
    Suzuki, Yasuo
    Motoya, Satoshi
    Hanai, Hiroyuki
    Matsumoto, Takayuki
    Hibi, Toshifumi
    Robinson, Anne M.
    Mostafa, Nael M.
    Chao, Jingdong
    Arora, Vipin
    Camez, Anne
    Thakkar, Roopal B.
    Watanabe, Mamoru
    JOURNAL OF GASTROENTEROLOGY, 2014, 49 (02) : 283 - 294
  • [27] SAFETY OF LONG-TERM OZANIMOD TREATMENT FOR UP TO 4 YEARS BY AGE GROUP IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: AN INTERIM ANALYSIS OF THE TRUE NORTH OPEN-LABEL EXTENSION
    Siegel, Corey A.
    Rubin, David T.
    Long, Millie D.
    Danese, Silvio
    Cross, Raymond K.
    Armuzzi, Alessandro
    Dignass, Axel
    Kobayashi, Taku
    Faye, Adam S.
    Lama, Sonie
    Charles, Lorna
    Cetin, Volkan
    Petersen, AnnKatrin
    Wu, Hsiuanlin
    Wang, Dong
    Jain, Anjali
    Sabino, Joao
    GASTROENTEROLOGY, 2024, 166 (05) : S805 - S806
  • [28] LONG-TERM SAFETY OF OFATUMUMAB IN PATIENTS WITH RELAPSING MULTIPLE SCLEROSIS
    Hauser, Stephen
    Cross, Anne
    Winthrop, Kevin
    Wiendl, Heniz
    Nicholas, Jacqueline
    Meuth, Sven
    Giacomini, Paul
    Sacca, Francesco
    Su, Wendy
    Kappos, Ludwig
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2022, 93 (09):
  • [29] Safety, Efficacy, and Pharmacokinetics of Golimumab in Patients with Moderately to Severely Active Ulcerative Colitis: PURSUIT-SC Long term Extension
    Reinisch, Walter
    Gibson, Peter R.
    Sandborn, William
    Feagan, Brian G.
    Marano, Colleen
    Strauss, Rick
    Johanns, Jewel
    Zhang, Hongyan
    Padgett, Lakshmi
    Adedokun, Omoniyi J.
    Colombel, Jean-Frederic
    Collins, Judith
    Rutgeerts, Paul J.
    Tarabar, Dino
    GASTROENTEROLOGY, 2016, 150 (04) : S776 - S777
  • [30] Malignancy Rates With Long-term Use of Ozanimod in Relapsing Multiple Sclerosis Trials
    Hartung, H-P.
    Cree, B. A. C.
    Selmaj, K. W.
    Havrdova, E. K.
    Comi, G.
    Sheffield, J. K.
    Minton, N.
    Lindholm, A.
    Ding, N.
    Bar-or, A.
    EUROPEAN JOURNAL OF NEUROLOGY, 2020, 27 : 330 - 331
12345